background
marburg
viru
marv
caus
sever
haemorrhag
fever
human
nonhuman
primat
high
mortal
rate
howev
effect
drug
licens
vaccin
current
avail
control
outbreak
spread
diseas
method
studi
gener
marv
viruslik
particl
vlp
coexpress
glycoprotein
gp
matrix
protein
use
baculoviru
express
system
marv
vlp
three
adjuv
poria
coco
polysaccharid
pcpii
poli
c
aluminium
hydroxid
evalu
intramuscular
vaccin
mice
result
murin
studi
demonstr
vaccin
marv
vlp
induc
neutral
antibodi
cellar
immun
respons
marv
vlp
pcpii
adjuv
group
result
high
titr
marvspecif
antibodi
activ
rel
higher
number
b
cell
cell
peripher
blood
mononuclear
cell
pbmc
induc
greater
cytokin
secret
splenocyt
adjuv
conclus
marv
vlp
pcpii
adjuv
may
constitut
effect
vaccin
pcpii
investig
novel
adjuv
marburg
viru
marv
belong
filovirida
famili
consist
nonseg
negativestrand
rna
virus
caus
sever
haemorrhag
fever
mortal
rate
first
recogn
marv
outbreak
occur
marburg
germani
import
infect
monkey
uganda
sinc
marv
caus
human
infect
death
recent
outbreak
occur
uganda
high
lethal
rate
rapid
onset
marv
virus
activ
pursu
past
potenti
biolog
weapon
current
vaccin
believ
best
option
prevent
marv
diseas
although
effect
treatment
licens
vaccin
marv
infect
current
avail
substanti
progress
made
search
marv
vaccin
past
sever
year
dna
vaccin
recombin
vesicular
stomat
viru
vector
vaccin
viruslik
particl
vlp
vaccin
demonstr
work
prophylact
vaccin
postexposur
treatment
anim
model
vlp
viral
protein
selfassembl
structur
resembl
conform
authent
nativ
viru
howev
lack
viral
genom
therefor
vlp
safe
success
develop
commerci
vaccin
candid
vaccin
porcin
circoviru
pcv
type
hepat
b
viru
hbv
human
papillomaviru
hpv
human
immunodefici
viru
hiv
high
yield
easi
construct
larg
packag
capac
insect
cell
baculoviru
express
system
commonli
use
vlp
studi
vlp
capabl
activ
cell
involv
innat
adapt
immun
induc
strong
humor
cellular
immun
respons
marv
genom
encod
follow
seven
structur
protein
nucleoprotein
np
virion
protein
vp
glycoprotein
gp
rnadepend
rna
polymeras
l
gp
primari
antigen
elicit
protect
immun
respons
previou
studi
show
gp
marv
assembl
vlp
mammalian
cell
vlp
capabl
confer
effect
protect
vaccin
lethal
marv
challeng
mice
induc
humor
cellular
immun
respons
subsequ
studi
vlp
contain
marv
gp
np
gener
use
baculoviru
express
system
demonstr
combin
confer
protect
guinea
pig
cynomolgu
macaqu
recent
show
coexpress
gp
insect
cell
also
led
effici
assembl
releas
vlp
electron
microscopi
find
indic
similar
morpholog
wildtyp
marv
present
trend
vaccin
develop
shown
antigen
often
lack
suffici
immunogen
thu
requir
addit
potent
adjuv
adjuv
tradit
use
increas
modul
humor
cellular
immun
respons
vaccin
antigen
reduc
vaccin
cost
limit
amount
requir
antigen
advanc
vaccin
technolog
mani
immun
potenti
adjuv
emerg
natur
polysaccharid
found
act
immunolog
enhanc
use
immunopotenti
enhanc
cellular
immun
promot
antibodi
product
polysaccharid
natur
safe
nonresidu
poria
coco
long
histori
medicin
use
china
olysaccharid
deriv
exhibit
mani
benefici
medicin
biolog
activ
includ
anticanc
antiinflammatori
antioxid
antivir
activ
previou
studi
new
polysaccharid
pcpii
isol
sclerotium
poria
coco
pcpii
molecular
weight
kda
consist
fucos
mannos
glucos
galactos
molar
ratio
respect
pcpii
stimul
significantli
antibodi
respons
extend
durabl
immun
inactivet
rabi
vaccin
influenza
hbsag
vaccin
studi
gener
vlp
insect
cell
coexpress
marv
gp
protein
use
recombin
baculoviru
express
system
assess
whether
marv
vlp
alon
adjuv
induc
specif
antibodi
cellular
immun
respons
evalu
immunogen
marv
vlp
mous
model
result
present
herein
spodoptera
frugiperda
insect
cell
cultur
serumfre
medium
life
technolog
san
diego
ca
usa
vv
penicillinstreptomycin
suspens
polyclon
antisera
marv
gp
protein
isol
mice
immun
gp
protein
express
prokaryot
express
system
respect
poli
c
sigma
usa
aluminium
hydroxid
alum
thermo
usa
purchas
pcpii
polysaccharid
kindli
provid
professor
junji
beij
institut
pharmacolog
toxicolog
gp
gene
sequenc
marv
obtain
genbank
access
respect
gene
codonoptim
highest
possibl
express
level
insect
cell
biochem
synthes
sangon
biotech
shanghai
china
gp
gene
insert
pfastbacdu
vector
invitrogen
carlsbad
ca
usa
control
polyhedron
promot
wherea
gene
insert
pfastbacdu
vector
control
promot
gener
recombin
plasmid
transform
e
coli
compet
cell
gener
recombin
bacmid
cell
transfect
recombin
bacmid
use
lipofectamin
accord
manufactur
instruct
invitrogen
recombin
baculovirus
harvest
day
transfect
expand
cell
gener
viru
stock
titr
baculoviru
stock
determin
use
bacpak
baculoviru
rapid
titr
kit
clontech
usa
insect
cell
infect
recombin
baculoviru
multipl
infect
moi
marv
vlp
collect
cultur
supernat
h
postinfect
clarifi
cell
debri
vlp
concentr
highspe
centrifug
purifi
discontinu
sucros
gradient
previous
describ
visibl
band
sucros
layer
collect
concentr
centrifug
resuspend
phosphat
buffer
salin
pb
cell
infect
recombin
baculovirus
h
fix
cold
aceton
min
room
temperatur
subsequ
cell
evalu
use
mous
polyclon
antibodi
marv
protein
marv
gp
final
concentr
contain
bovin
serum
albumin
h
room
temperatur
three
wash
pb
tween
pbst
block
pbst
plu
bsa
h
room
temperatur
secondari
antibodi
fitclabel
goat
antimous
igg
ad
evan
blue
h
cell
analys
fluoresc
microscop
electron
microscopi
analysi
marv
vlp
appli
carbonco
formvar
grid
neg
stain
phosphotungst
acid
observ
via
transmiss
electron
microscopi
tem
marv
vlp
analys
sdspage
denatur
condit
protein
transfer
onto
polyvinyliden
fluorid
pvdf
membran
immobilinp
millipor
usa
western
blot
analysi
mous
polyclon
antibodi
marv
protein
marv
gp
detect
perform
goat
antimous
horseradish
peroxideconjug
antibodi
enhanc
chemiluminesc
protein
concentr
purifi
marv
vlp
analys
use
bca
assay
kit
thermo
sixtoeightweekold
femal
balbc
mice
randomli
divid
group
mice
per
group
vaccin
intramuscularli
im
twice
marv
vlp
alon
mix
differ
studi
adjuv
immun
perform
studi
day
control
mice
vaccin
pb
time
point
vaccin
inject
either
pcpii
poli
c
alum
adjuv
mix
marv
vlp
vaccin
blood
collect
mice
day
peripher
blood
mononuclear
cell
pbmc
collect
mice
group
day
first
immun
singl
cell
suspens
cellsml
prepar
pb
stain
antimous
antibodi
bd
bioscienc
franklin
tn
usa
label
b
cell
antimous
monoclon
antibodi
bd
bioscienc
usa
label
cell
splenocyt
isol
two
week
second
vaccin
splenocyt
suspens
cellsml
stimul
purifi
gp
associ
protein
transport
inhibitor
bd
bioscienc
h
poststimul
surfac
stain
perform
monoclon
antibodi
h
cell
permeabil
cytofixcytoperm
bd
bioscienc
stain
monoclon
antibodi
bd
bioscienc
respect
h
label
cell
wash
twice
pb
cell
analys
lsrii
flow
cytomet
bd
bioscienc
detect
level
cytokin
splenocyt
cellsml
isol
day
second
vaccin
suspend
rpmi
medium
contain
foetal
bovin
serum
fb
splenocyt
suspens
stimul
purifi
gp
incub
h
supernat
stimul
cell
measur
use
murin
elisa
kit
accord
manufactur
instruct
mabtech
ab
sweden
splenocyt
vaccin
mice
isol
week
second
immun
stimul
purifi
gp
h
splenocyt
produc
quantifi
mous
elispot
kit
mous
elispot
kit
mabtech
ab
stockholm
sweden
accord
manufactur
instruct
spotform
cell
sfc
count
use
autom
elispot
reader
aid
elispot
readerispot
aid
gmbh
ger
marv
gppseudotyp
viru
prepar
neutral
antibodi
nab
titr
determin
perform
previous
describ
briefli
pcaggmarvg
cotransfect
cell
cultur
dish
supernat
harvest
h
centrifug
remov
cell
debri
store
titrat
assay
serial
dilut
pseudotyp
viru
incub
vero
cell
h
luciferas
activ
measur
use
multifunct
micropl
reader
infinit
tecan
austria
gmbh
austria
neutral
assay
twofold
serial
dilut
rang
prepar
quadrupl
dilut
serum
sampl
ad
x
tcid
pseudotyp
viru
prepar
equal
volum
sera
incub
min
addit
vero
cell
incub
h
medium
replac
dmem
contain
fb
plate
incub
h
luciferas
activ
measur
use
infinit
neutral
dose
nd
calcul
use
graphpad
prism
marvspecif
antibodi
determin
indirect
elisa
briefli
assay
perform
polystyren
microtit
plate
corn
costar
usa
precoat
purifi
gp
protein
concentr
overnight
block
h
serial
dilut
serum
sampl
incub
h
hrpconjug
goat
antimous
igg
polyclon
antibodi
abcam
uk
dilut
incub
h
substrat
tmb
sigma
usa
ad
well
incub
h
stop
h
infinit
use
measur
optic
densiti
nm
data
present
mean
standard
error
mean
sem
statist
analys
perform
use
spss
softwar
spss
inc
chicago
il
usa
determin
statist
signific
differ
gener
data
via
oneway
analysi
varianc
anova
signific
differ
determin
kaplanmei
analysi
result
consid
signific
p
signific
p
gp
gene
base
musok
strain
marv
clone
pfastbacdu
vector
recombin
plasmid
transfect
cell
obtain
recombin
baculoviru
express
gp
recombin
baculoviru
confirm
ifa
expect
result
demonstr
express
gp
protein
fig
cell
infect
recombin
baculoviru
moi
mixtur
supernat
cell
analys
via
western
blot
fig
tem
fig
marv
vlp
produc
infect
cell
purifi
sucros
gradient
analys
western
blot
shown
fig
protein
band
molecular
weight
kd
correspond
gp
detect
marv
vlp
protein
also
readili
detect
vlp
molecular
weight
kd
fig
howev
specif
band
gp
detect
control
sampl
lane
gener
vlp
resembl
nativ
marv
virion
diamet
approxim
nm
fig
evalu
immunogen
marv
vlp
serum
igg
concentr
immun
mice
determin
via
elisa
day
week
immun
mice
immun
marv
vlp
strong
humor
respons
compar
observ
pb
group
pcpii
group
higher
igg
titr
anim
administ
marv
vlp
alon
p
fig
mice
immun
pcpii
adjuv
higher
respons
endpoint
titr
vaccin
poli
c
alum
adjuv
p
fig
anim
vaccin
marv
vlp
mix
poli
c
alum
adjuv
similar
respons
gp
antigen
endpoint
titr
fig
nab
titr
mice
immun
marv
vlp
higher
pb
group
fig
day
week
immun
furthermor
mice
vaccin
pcpii
adjuv
higher
nab
titr
vaccin
poli
c
alum
adjuv
p
nab
titr
mice
vaccin
marv
vlp
higher
pb
group
nab
titr
pcpii
group
determin
dilut
second
immun
fig
day
week
immun
mice
vaccin
pcpii
adjuv
higher
nab
titr
vaccin
marv
vlp
poli
c
endpoint
titr
p
alum
endpoint
titr
p
nab
titr
control
pb
group
limit
detect
endpoint
titr
assess
tcell
respons
mice
follow
vaccin
use
elispot
assay
detect
secret
mous
splenocyt
higher
number
sfc
observ
mice
inject
pcpii
mice
group
fig
b
also
level
secret
mice
vaccin
marv
vlp
higher
observ
control
mice
pcpii
group
sfc
wherea
group
approxim
sfc
pcpii
group
sfc
wherea
group
approxim
sfc
overal
result
suggest
abil
pcpii
boost
cellmedi
immun
respons
marv
vlp
vaccin
superior
poli
c
alum
character
tcell
respons
induc
marv
vlp
evalu
abil
marv
vlp
plu
adjuv
induc
secret
cell
intracellular
cytokin
stain
ic
assay
compar
control
group
marv
vlp
pcpii
induc
higher
number
cell
p
fig
c
marv
vlp
pcpii
induc
higher
number
cell
adjuv
group
p
fig
c
similar
result
observ
secret
cell
fig
marv
vlp
pcpii
induc
rel
higher
number
cell
adjuv
group
p
fig
statist
signific
differ
observ
poli
c
alum
group
vlponli
group
data
demonstr
mice
immun
marv
vlp
contain
pcpii
significantli
enhanc
tcell
respons
investig
whether
pcpii
activ
b
cell
mice
adjuv
lymphocyt
isol
pbmc
collect
tcell
bcell
isol
fig
show
bcell
activ
fig
c
show
tcell
recruit
blood
cytokin
level
measur
duplic
use
commerci
elisa
kit
level
secret
splenocyt
isol
mice
marv
vlp
group
higher
control
group
fig
level
pcpii
group
significantli
higher
adjuv
group
p
p
secret
respons
ifnr
associ
profil
wherea
secret
respons
associ
immun
respons
studi
gener
typic
marv
vlp
coexpress
two
viral
gene
gp
insect
cell
compar
coinfect
three
viral
gene
form
vlp
kind
program
coexpress
gp
could
improv
level
vlp
express
enhanc
packag
effici
due
multipl
cultur
advantag
insect
cellbaculoviru
express
vector
system
power
platform
product
vlp
includ
abil
reach
high
cell
densiti
suspens
cultur
high
protein
express
level
provid
eukaryot
posttransl
process
adjuv
compound
increas
modul
intrins
immunogen
antigen
elicit
stronger
immun
respons
adjuv
gener
characterist
immun
respons
profil
differ
adjuv
suitabl
differ
antigen
howev
alum
wide
use
adjuv
may
caus
side
poli
c
synthet
doublestrand
rna
demonstr
potent
adjuv
abil
enhanc
host
innat
adapt
immun
respons
polysaccharid
emerg
new
type
adjuv
use
stimul
rapid
immun
respons
thu
serv
highli
valuabl
addit
boost
vaccin
immunogen
ribi
adjuv
use
mani
marv
vlp
studi
studi
immunogen
marv
vlp
alon
mix
poli
c
alum
pcpii
vaccin
evalu
mice
result
show
vaccin
marv
vlp
stimul
robust
immun
respons
cellar
immun
respons
mice
addit
pcpii
significantli
enhanc
specif
antibodi
respons
nab
titr
marv
vlp
compar
adjuv
marv
vlp
alon
mice
first
immun
notabl
second
immun
mice
pcpii
group
still
produc
higher
level
nab
adjuv
group
highest
overal
level
antibodi
day
immun
compar
mice
adjuv
group
mice
pcpii
group
induc
higher
level
lgg
second
vaccin
administr
vaccin
compos
marv
vlp
adjuv
pcpii
adjuv
result
signific
increas
secret
relat
cytokin
relat
cytokin
studi
splenocyt
mice
immun
marv
vlp
also
produc
stronger
respons
stimul
arm
adapt
immun
respons
result
show
marv
vlp
pcpii
boost
immun
respons
pathway
indic
higher
number
activ
b
fig
serum
antibodi
respons
marv
vlp
analysi
antibodi
respons
elisa
serum
sampl
obtain
week
vaccin
total
serum
antibodi
assay
marv
gpspecif
antibodi
use
elisa
purifi
gp
coat
antigen
antibodi
titr
measur
individu
mice
result
graph
geometr
mean
titr
group
n
b
neutral
marv
gppseudotyp
viru
serum
sampl
incub
marv
gppseudotyp
viru
vero
cell
titr
shown
highest
serum
dilut
reduc
luciferas
activ
well
nt
express
mean
sd
statist
signific
analys
use
oneway
anova
p
p
p
fig
elispot
analysi
secret
splenocyt
spleen
collect
mice
per
group
day
second
vaccin
splenocyt
assay
elispot
ic
assay
sfc
secret
b
measur
use
elispot
data
repres
mean
sd
sfc
per
million
splenocyt
mice
group
statist
signific
analys
use
oneway
anova
p
p
p
fig
ic
assay
antigenspecif
tcell
secret
splenocyt
marvspecif
cell
measur
via
ic
assay
spleen
prepar
mice
per
group
stain
mous
antibodi
cell
secret
b
cell
secret
c
shown
data
repres
mean
sd
statist
signific
analys
use
oneway
anova
p
p
p
fig
flow
cytometri
analysi
b
cell
isol
pbmc
mice
pbmc
isol
mice
group
first
immun
identifi
follow
marker
b
cell
cell
doubleposit
b
c
cell
plot
repres
data
shown
mean
sem
statist
signific
analys
use
oneway
anova
p
p
p
p
lymphocyt
circul
blood
vaccin
adjuv
combin
mice
administ
adjuv
turn
enhanc
immun
may
also
result
higher
broader
serum
antibodi
subclass
respons
lymphocyt
divid
cell
mediat
antigenspecif
cellular
immun
respons
analys
capac
adjuv
induc
secret
cell
ic
assay
perform
result
ic
assay
show
pcpii
adjuv
activ
rel
higher
number
cell
secret
cell
activ
macrophag
therebi
increas
kill
phagocytos
microb
howev
produc
cell
drive
matur
b
cell
plasma
cell
therebi
result
antibodi
product
isotypeswitch
affin
matur
result
indic
pcpii
act
adjuv
stimul
stronger
type
respons
therefor
superior
poli
c
alum
adjuv
specif
humor
cellmedi
immun
essenti
effect
vaccin
mani
pathogen
present
studi
pcpii
may
effect
induc
stronger
humor
cellular
immun
adjuv
use
conjunct
marv
vlp
vaccin
due
lack
anim
model
current
anim
model
costli
obtain
first
test
vaccin
candid
regimen
immunogen
mice
model
possibl
perform
challeng
experi
confirm
enhanc
immun
lead
better
protect
advanc
bestperform
candid
suitabl
anim
model
marv
compar
pcpii
ribi
futur
studi
summari
pcpii
adjuv
marv
vlp
promis
vaccin
regimen
next
stage
preclin
test
larger
anim
model
dosag
rout
administr
interv
immun
need
evalu
optim
maxim
chanc
success
vaccin
work
highlight
potenti
use
pcpii
develop
marv
vlp
vaccin
use
human
fig
elisa
result
show
quantiti
secret
splenocyt
splenocyt
prepar
mice
per
group
week
second
vaccin
cellfre
supernat
harvest
h
incub
measur
determin
level
pgml
b
c
via
elisa
duplic
repres
data
shown
mean
sd
mice
per
group
analys
use
oneway
anova
p
p
p
